What do systematic reviews say?

Hysterectomy (simple or radical) with radiotherapy vs Radiotherapy alone

Hysterectomy (simple or radical) with radiotherapy showed no clear difference in progression‐free survival Median compared with radiotherapy alone (low certainty).

• Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer 2022 · Cochrane Headline outcomes only
  HR 0.77 [0.54, 1.1]
  1 study · 256 participants
  Low

Large‐volume residual disease (LVRD) > 1 cm vs small‐volume residual disease (SVRD) < 1 cm

It is very uncertain whether large‐volume residual disease (LVRD) > 1 cm changes progression‐free survival: Median length of compared with small‐volume residual disease (SVRD) < 1 cm (very low certainty).

• Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after… 2022 · Cochrane Headline outcomes only
  HR 1.76 [1.23, 2.52]
  4 studies · 1145 participants
  Very low

Residual disease (RD) > 0 cm vs NMRD

It is very uncertain whether residual disease (RD) > 0 cm changes progression‐free survival: Median length of compared with NMRD (very low certainty).

• Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after… 2022 · Cochrane Headline outcomes only
  HR 1.36 [1.05, 1.76]
  1 study · 471 participants
  Very low

Small‐volume residual disease (SVRD) (< 1 cm) vs NMRD

Small‐volume residual disease (SVRD) < 1 cm probably leads to higher progression‐free survival: Median length of compared with NMRD (moderate certainty).

• Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after… 2022 · Cochrane Headline outcomes only
  HR 1.88 [1.63, 2.16]
  10 studies · 6596 participants
  Moderate

Large‐volume residual disease (LVRD) > 1 cm vs NMRD

Large‐volume residual disease (LVRD) > 1 cm probably leads to higher progression‐free survival: Median length of compared with no macroscopic residual disease (NMRD) (moderate certainty).

• Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after… 2022 · Cochrane Headline outcomes only
  HR 2.1 [1.84, 2.4]
  6 studies · 2629 participants
  Moderate

Large‐volume residual disease (LVRD) > 1 cm vs small‐volume residual disease (SVRD) < 1 cm

Large‐volume residual disease (LVRD) > 1 cm probably leads to higher progression‐free survival: Median length of compared with small‐volume residual disease (SVRD) < 1 cm (moderate certainty).

• Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after… 2022 · Cochrane Headline outcomes only
  HR 1.3 [1.08, 1.56]
  2 studies · 3402 participants
  Moderate

Small‐volume residual disease (SVRD) (< 1 cm) vs NMRD

• Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 322 participants
  Very low

Hysterectomy (simple or radical) with neoadjuvant chemotherapy vs Radiotherapy alone

Hysterectomy (simple or radical) with neoadjuvant chemotherapy showed no clear difference in disease‐ or progression‐free survival Median compared with radiotherapy alone (moderate certainty).

• Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer 2022 · Cochrane Headline outcomes only
  HR 0.75 [0.53, 1.05]
  3 studies · 571 participants
  Moderate